ValuEngine cut shares of United Therapeutics Corporation (NASDAQ:UTHR) from a strong-buy rating to a buy rating in a report released on Friday morning.

Several other research analysts have also recently weighed in on UTHR. Jefferies Group LLC reaffirmed a sell rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Oppenheimer Holdings, Inc. reaffirmed a buy rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. UBS AG reaffirmed a sell rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. BidaskClub cut United Therapeutics Corporation from a buy rating to a hold rating in a research report on Wednesday, July 19th. Finally, J P Morgan Chase & Co set a $125.00 price objective on United Therapeutics Corporation and gave the stock a hold rating in a research report on Tuesday, April 11th. Six equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation has a consensus rating of Hold and a consensus target price of $134.50.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 128.40 on Friday. The firm’s 50-day moving average price is $130.80 and its 200-day moving average price is $136.41. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of 14.89 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. During the same quarter last year, the company earned $4.42 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post $14.40 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-rating-lowered-to-buy-at-valuengine/1465668.html.

United Therapeutics Corporation declared that its Board of Directors has approved a stock repurchase plan on Thursday, April 27th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the biotechnology company to purchase up to 4.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its stock is undervalued.

In related news, CEO Martine A. Rothblatt sold 1,265 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $119.40, for a total transaction of $151,041.00. Following the completion of the transaction, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at $167,757. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $122.24, for a total value of $153,777.92. Following the transaction, the chief executive officer now directly owns 1,398 shares of the company’s stock, valued at $170,891.52. The disclosure for this sale can be found here. Insiders have sold 23,768 shares of company stock valued at $3,054,718 over the last three months. Insiders own 7.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Dock Street Asset Management Inc. boosted its stake in United Therapeutics Corporation by 21.5% in the first quarter. Dock Street Asset Management Inc. now owns 35,455 shares of the biotechnology company’s stock worth $4,800,000 after buying an additional 6,280 shares during the last quarter. Meritage Portfolio Management boosted its stake in United Therapeutics Corporation by 1.3% in the first quarter. Meritage Portfolio Management now owns 37,801 shares of the biotechnology company’s stock worth $5,117,000 after buying an additional 502 shares during the last quarter. Profund Advisors LLC boosted its stake in United Therapeutics Corporation by 0.8% in the first quarter. Profund Advisors LLC now owns 24,714 shares of the biotechnology company’s stock worth $3,346,000 after buying an additional 187 shares during the last quarter. Korea Investment CORP boosted its stake in United Therapeutics Corporation by 1.6% in the first quarter. Korea Investment CORP now owns 97,700 shares of the biotechnology company’s stock worth $13,227,000 after buying an additional 1,500 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in United Therapeutics Corporation by 5.6% in the first quarter. Nationwide Fund Advisors now owns 109,868 shares of the biotechnology company’s stock worth $14,874,000 after buying an additional 5,789 shares during the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.